Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Vaccination regimen effective in preventing pneumonia in MM patients

Publish date:: May 21, 2020

Key clinical point: Vaccination was effective despite the expected decrease in immunological response during MM therapy.

Major finding: The absolute risk reduction of pneumonias in patients receiving PCV13 vaccination was

33.3%.

Study details: Prospective study of 18 adult patients who were vaccinated with PCV13, compared with 18 control-matched patients from 2017 to 2020.

Disclosures: The authors reported that they had no relevant disclosures.

Citation:

Stoma I et al. Vaccine. 2020 May 14; doi.org/10.1016/j.vaccine.2020.05.024.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Multiple Myeloma

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Durable responses with anti-BCMA CAR T-cell for multiple myeloma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,